CGON241220C30000
- 5.50
- 0.000.00%
CG Oncology Newsroom
RBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $66
Morgan Stanley Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $55
CG Oncology Analyst Ratings
CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
Analysts Offer Insights on NA Companies: CG Oncology, Inc. (CGON), Smith Douglas Homes Corp. Class A (SDHC) and Palmer Square Capital BDC Inc. (PSBD)
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $75
CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
CG Oncology's Strategic Growth and Promising Therapeutic Developments Reinforce Buy Rating
Morgan Stanley Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $55
CG Oncology Analyst Ratings
UBS Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $60
CG Oncology Initiated With a Buy at UBS
BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $65
CG Oncology Is Maintained at Buy by B of A Securities
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
Buy Rating Affirmed for CG Oncology Amidst Bladder Cancer Market Opportunities
BofA Securities Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $65
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86